partnering

News

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Jazz Pharma has lost little time in deciding to buy into Zymeworks' HER2-directed bispecific antibody zanidatamab, paying $325 million upfront for rights to the drug just weeks after taking

News

close up of a prescription bottle with white tables falling out on top of a group of hundred dollar bills

Sosei nets $10m Pfizer milestone as diabetes/obesity drug st...

Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established ri

News

Sanofi backs out of $500m cancer alliance with Revolution

Sanofi has walked away from a four-year-old partnership with Revolution Medicines focused on an SHP2 inhibitor, intended as a combination with KRAS inhibitors, including Sanofi’s Mirati-par

News

GSK's pullback from cell therapy continues as Immatics allia...

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.

News

Roche deepens ties with Jnana with a second licensing deal

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-rangin

News

Lantheus on POINT in radio-oncology with $2bn licensing deal

Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Sosei nets $10m Pfizer milestone as diabetes/obesity drug st...

Sanofi backs out of $500m cancer alliance with Revolution

GSK's pullback from cell therapy continues as Immatics allia...

Roche deepens ties with Jnana with a second licensing deal

Lantheus on POINT in radio-oncology with $2bn licensing deal

EU clears AZ's SERD camizestrant, as FDA review drags on

Discover a new era of healthcare panel engagement: Grounded ...

partnering

Editor's Picks